Skip to content
10-Q

Quarterly Report

Artiva Biotherapeutics, Inc. ARTV

0000950170-25-066421

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 24.36M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $135.56M
Short Term Investments Q1 2025 · Dec 31, 2024 $145.19M
Current Liabilities Q1 2025 · Mar 31, 2025 $12.2M
Current Liabilities Q1 2025 · Dec 31, 2024 $12.25M
Total Liabilities Q1 2025 · Mar 31, 2025 $22.48M
Total Liabilities Q1 2025 · Dec 31, 2024 $22.94M
Current Assets Q1 2025 · Mar 31, 2025 $170M
Current Assets Q1 2025 · Dec 31, 2024 $188.63M
Total Assets Q1 2025 · Mar 31, 2025 $191.26M
Total Assets Q1 2025 · Dec 31, 2024 $209.58M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $40.24M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $48.2M
Shares Diluted Q1 2025 · Mar 31, 2024 809.76K sh
Capex Q1 2025 · Mar 31, 2024 $18K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$15.09M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$174.67M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$162.02M
Eps Diluted Q1 2025 · Mar 31, 2024 −$17.24
Eps Basic Q1 2025 · Mar 31, 2024 −$17.24
Sga Expense Q1 2025 · Mar 31, 2024 $3.59M
Rd Expense Q1 2025 · Mar 31, 2024 $11.16M
Net Income Q1 2025 · Mar 31, 2024 −$13.96M
Operating Income Q1 2025 · Mar 31, 2024 −$14.49M